CSIMarket
 


Kaleido Biosciences Inc   (KLDO)
Other Ticker:  
 

Kaleido Biosciences Inc 's Total Debt to Equity

KLDO's quarterly Total Debt to Equity and Total Debt, Equity growth


Due to net new borrowings of 1.64%, Total Debt to Equity fell to 2.05, a new company high.

Within Biotechnology & Pharmaceuticals industry in the forth quarter 2021, 66 other companies have achieved lower Total Debt to Equity than Kaleido Biosciences Inc in the IV Quarter 2021. While Total Debt to Equity total ranking has deteriorated compared to the second quarter 2021 from 1671 to 3114 .

Explain Debt to Equity Ratio?
What is the structure of KLDO´s Total Debt?
How valuable is the KLDO´s Equity?


KLDO Total Debt to Equity (Dec 31 2021)
IV. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Equity Change -70.45 % -2.06 % 113.48 % -58.07 % -45.64 %
Y / Y Total Debt Change 4.16 % 3.34 % 3.05 % 3.03 % 40.09 %
Total Debt to Equity MRQ 2.05 0.42 0.3 1.03 0.58
KLDO's Total Ranking # 3114 # 1671 # 817 # 1280 #
Seq. Equity Change -78.9 % -29.97 % 250.19 % -42.91 % -30.05 %
Seq. Total Debt Change 1.64 % 0.72 % 0.87 % 0.87 % 0.84 %



Total Debt to Equity forth quarter 2021 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 67
Healthcare Sector # 506
Overall Market # 3114


Total Debt to Equity Statistics
High Average Low
2.05 0.58 0.14
(Dec 31 2021)   (Mar 31 2019)




Financial Statements
Kaleido Biosciences Inc 's Equity $ 11 Millions Visit KLDO's Balance sheet
Kaleido Biosciences Inc 's Total Debt $ 22 Millions Visit KLDO's Balance sheet
Source of KLDO's Sales Visit KLDO's Sales by Geography


Cumulative Kaleido Biosciences Inc 's Total Debt to Equity

KLDO's Total Debt to Equity for the trailling 12 Months

KLDO Total Debt to Equity

(Dec 31 2021)
IV. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Equity TTM Growth -70.45 % -2.06 % 113.48 % -58.07 % -45.64 %
Y / Y Total Debt TTM Growth 4.16 % 3.34 % 3.05 % 3.03 % 40.09 %
Total Debt to Equity TTM 0.56 0.47 0.47 0.59 0.49
Total Ranking TTM # 417 # 1479 # 2037 # 770 #
Seq. Equity TTM Growth -78.9 % -29.97 % 250.19 % -42.91 % -30.05 %
Seq. Total Debt TTM Growth 1.64 % 0.72 % 0.87 % 0.87 % 0.84 %


On the trailing twelve months basis Due to the net new borrowings of 1.64% during the trailing twelve months finishing in the IV Quarter 2021, cumulativeTotal Debt to Equity improved to 0.56, a new company high.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 20, during the past 12 months, other companies have achieved lower Total Debt to Equity than Kaleido Biosciences Inc . While Total Debt to Equity total ranking has improved so far to 417, from total ranking in previous 12 month period at 1479.

Explain Debt to Equity Ratio?
What is the structure of KLDO´s Total Debt?
How valuable is the KLDO´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 21
Healthcare Sector # 107
Within the Market # 417


trailing twelve months Total Debt to Equity Statistics
High Average Low
0.56 0.1 0
(Dec 31 2021)   (Dec 31 2019)




Companies with similar Total Debt to Equity in the quarter ending Dec 31 2021, within Biotechnology & Pharmaceuticals Industry Total Debt to EquityDec 31 2021 MRQ Total DebtDec 31 2021 MRQ Equity
Amgen Inc   4.97 $ 33,309.000  Millions$ 6,700.000  Millions
Halozyme Therapeutics Inc   4.45 $ 876.674  Millions$ 196.953  Millions
Coherus Biosciences inc   3.90 $ 381.160  Millions$ 97.726  Millions
Kaleido Biosciences Inc   2.05 $ 21.694  Millions$ 10.607  Millions
Sorrento Therapeutics Inc   1.83 $ 142.607  Millions$ 78.129  Millions
Gamida Cell Ltd   1.66 $ 73.057  Millions$ 43.937  Millions
Elutia inc   1.37 $ 18.469  Millions$ 13.521  Millions
Inhibrx Inc   1.35 $ 70.470  Millions$ 52.383  Millions
Nanostring Technologies Inc   1.27 $ 225.144  Millions$ 176.962  Millions
Gilead Sciences Inc   1.27 $ 26,695.000  Millions$ 21,064.000  Millions
Acorda Therapeutics Inc   1.18 $ 178.670  Millions$ 151.137  Millions
Axcella Health Inc   1.14 $ 25.070  Millions$ 22.008  Millions
Oyster Point Pharma Inc   0.90 $ 89.815  Millions$ 99.537  Millions
Avalon Globocare Corp   0.89 $ 2.750  Millions$ 3.084  Millions
Adma Biologics Inc   0.67 $ 94.866  Millions$ 141.173  Millions
Erytech Pharma S a   0.67 $ 17.060  Millions$ 25.586  Millions
Biogen Inc   0.66 $ 7,273.100  Millions$ 10,959.700  Millions
Qiagen N v   0.63 $ 1,941.770  Millions$ 3,096.550  Millions
Pluri Inc   0.58 $ 23.158  Millions$ 39.840  Millions
Eloxx Pharmaceuticals Inc   0.54 $ 11.996  Millions$ 22.384  Millions
Allena Pharmaceuticals Inc.  0.52 $ 9.852  Millions$ 18.868  Millions
Xtant Medical Holdings Inc   0.50 $ 15.407  Millions$ 30.883  Millions
Codiak Biosciences Inc   0.48 $ 25.430  Millions$ 53.505  Millions
Outlook Therapeutics Inc   0.46 $ 22.321  Millions$ 48.823  Millions
Eiger Biopharmaceuticals Inc   0.44 $ 31.795  Millions$ 72.399  Millions
Rubius Therapeutics Inc   0.43 $ 76.154  Millions$ 178.782  Millions
Cannabis Global Inc.  0.41 $ 1.708  Millions$ 4.145  Millions

Date modified: 2023-03-22T15:32:47+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com